Diabetes, Obesity & Metabolism

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m²: A Target Trial Emulation

By Shao-Chia Chen, Yu-Nan Huang, Pei-Yun Li, Pen-Hua Su

Figure 1. Study flow and matched cohort assembly. — Figure 1. Study flow and matched cohort assembly.Study flow and matched cohort assembly.Chen et al.

Cohort study of 8,969 peopleInterventions

Declared no competing interests

The paper

Shao-Chia Chen, Yu-Nan Huang, Pei-Yun Li, Pen-Hua Su

Chung Shan Medical University Hospital

Diabetes, Obesity & Metabolism, 25 Aug 2026

doi.org/10.1111/dom.71266 PubMed 42642357

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression